Toll Free: 1-888-928-9744

Cholera - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cholera - Pipeline Review, H1 2016

Summary
Global Markets Direct's, 'Cholera - Pipeline Review, H1 2016', provides an overview of the Cholera pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cholera and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Cholera - The report reviews pipeline therapeutics for Cholera by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cholera therapeutics and enlists all their major and minor projects - The report assesses Cholera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cholera Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cholera - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Cholera Overview 7 Therapeutics Development 8 Pipeline Products for Cholera - Overview 8 Pipeline Products for Cholera - Comparative Analysis 9 Cholera - Therapeutics under Development by Companies 10 Cholera - Therapeutics under Investigation by Universities/Institutes 11 Cholera - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Cholera - Products under Development by Companies 15 Cholera - Products under Investigation by Universities/Institutes 16 Cholera - Companies Involved in Therapeutics Development 17 Akthelia Pharmaceuticals Limited 17 Beijing Minhai Biotechnology Co., Ltd 18 PaxVax, Inc. 19 Cholera - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 AKT-10082 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 cholera (trivalent) vaccine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 cholera [strain O1/El/Tor/Ogawa] vaccine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 crofelemer DR - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 gram-negative bacterial infections vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 IMSUTMR-1501 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 PXVX-0200 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules for Bacterial Infections - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Synthetic Peptides to Disrupt Cell Wall for Bacterial and Fungal Infections - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Cholera - Recent Pipeline Updates 42 Cholera - Dormant Projects 46 Cholera - Discontinued Products 47 Cholera - Product Development Milestones 48 Featured News & Press Releases 48 Dec 16, 2015: U.S. Food and Drug Administration Accepts Biologics License Application for PaxVax's Single-Dose Oral Cholera Vaccine Vaxchora 48 Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix 48 Dec 08, 2014: PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial 49 Sep 30, 2014: Specialty Vaccine Company PaxVax to Present at 13th Annual BIO Investor Forum 50 Jul 01, 2014: Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study 50 May 27, 2014: Specialty Vaccine Company PaxVax to Present at the Jefferies 2014 Global Healthcare Conference 51 Jan 09, 2014: PaxVax Announces Positive Interim Results for Phase 3 Cholera Challenge Study; Clinical Trial Program to Proceed as Planned 52 Sep 06, 2013: PaxVax Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine 53 Nov 14, 2012: PaxVax Presents Phase I Clinical Trial Results Of Single-dose Cholera Vaccine At 2012 ASTMH Annual Meeting 54 Mar 19, 2012: FDA Accepts PaxVax's IND for Single-Dose Oral Cholera Vaccine 55 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 56 Disclaimer 57
List of Tables
Number of Products under Development for Cholera, H1 2016 8 Number of Products under Development for Cholera - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Cholera - Pipeline by Akthelia Pharmaceuticals Limited, H1 2016 17 Cholera - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 18 Cholera - Pipeline by PaxVax, Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Cholera Therapeutics - Recent Pipeline Updates, H1 2016 42 Cholera - Dormant Projects, H1 2016 46 Cholera - Discontinued Products, H1 2016 47



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify